CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma

CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma

BackgroundBecause of the high incidence and poor prognoses of lung adenocarcinoma (LUAD), it is essential to identify cost-effective treatment options and accurate and reliable prognostic biomarkers. CDCA4 upregulation has been identified in many cancers. However, the prognostic importance of CDCA4...

Full description

Bibliographic Details
Main Authors: Jianlong Tan, Fengyu Chen, Bin Ouyang, Xiuying Li, Weidong Zhang, Xinglin Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
CDCA4
lung adenocarcinoma
biomarker
prognosis
TCGA
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.865756/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.865756/full

Similar Items